Simcere Pharmaceutical Group (S2P) Stock Overview
An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
S2P Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Simcere Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.29 |
| 52 Week High | HK$1.60 |
| 52 Week Low | HK$1.00 |
| Beta | 0.73 |
| 1 Month Change | -9.79% |
| 3 Month Change | 14.16% |
| 1 Year Change | -12.84% |
| 3 Year Change | 76.71% |
| 5 Year Change | 57.32% |
| Change since IPO | -11.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| S2P | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.5% | 0.9% | -0.6% |
| 1Y | -12.8% | 38.6% | 2.7% |
Return vs Industry: S2P underperformed the German Pharmaceuticals industry which returned 41.2% over the past year.
Return vs Market: S2P underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| S2P volatility | |
|---|---|
| S2P Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: S2P's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: S2P's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 7,038 | Yunshu Zhou | www.simcere.com |
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clinical trials. The company also develops SIM0270, a new-generation oral SERD with blood-brain barrier penetration characteristics; Denlorlatinib; SIM0395, a BBB-penetrant inhibitor of the PI3K/mTOR pathway; and deuterated remdesivir hydrobromide dry suspension that are in Phase 3 clinical trial, as well as Sanbexin an injection new indication; Sanbexin a sublingual tablets; and SIM0278, a Fc fusion protein (IL2muFc) with an IL2 mutein of regulatory T cells that is in Phase 2 clinical trials.
Simcere Pharmaceutical Group Limited Fundamentals Summary
| S2P fundamental statistics | |
|---|---|
| Market cap | €3.39b |
| Earnings (TTM) | €200.20m |
| Revenue (TTM) | €1.11b |
Is S2P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S2P income statement (TTM) | |
|---|---|
| Revenue | CN¥8.73b |
| Cost of Revenue | CN¥1.50b |
| Gross Profit | CN¥7.23b |
| Other Expenses | CN¥5.66b |
| Earnings | CN¥1.57b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.61 |
| Gross Margin | 82.86% |
| Net Profit Margin | 18.01% |
| Debt/Equity Ratio | 11.2% |
How did S2P perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/21 13:18 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Simcere Pharmaceutical Group Limited is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shaojing Tong | BofA Global Research |
| Bo Yu | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |